Skip to content
Yog Pharma
Respiratory and allergyH1 antihistamine (R-enantiomer of cetirizine)

Levocetirizine Dihydrochloride is an H1 antihistamine (R-enantiomer of cetirizine) indicated for allergic rhinitis and chronic idiopathic urticaria. We supply it to US manufacturers of tablets and oral solution.

CAS130018-87-0461.8 g/molC21H27Cl3N2O3
2D structure of Levocetirizine Dihydrochloride, shown as the active moiety without counter-ion or water of hydration.

Data from PubChem (CID 9955977) and FDA’s substance registry

CAS number

130018-87-0

Molecular formula

C21H27Cl3N2O3

Molecular weight

461.8g/mol

FDA UNII

IUPAC name

2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid;dihydrochloride

InChIKey

PGLIUCLTXOYQMV-GHVWMZMZSA-N

Appearance
White or almost white powder.
Solubility
Freely soluble in water, and practically insoluble in acetone and methylene chloride.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

The R-enantiomer of cetirizine. The limit for the S-enantiomer is the figure to compare between sources.

On the US market

Reference product
XyzalNDA 022064
Approved ANDAs
16 with a marketed product
Approved forms and strengths
  • Tablet 5 mg
  • Oral solution 2.5 mg/5 mL

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com